Rituximab chimeric anti-CD20 monoclonal antibody treatment for refractory hemolytic anemia in patients with lymphoproliferative disorders

被引：0
|
作者：
Trapè, G [1 ]
Fianchi, L [1 ]
Lai, M [1 ]
Laurenti, L [1 ]
Piscitelli, R [1 ]
Leone, G [1 ]
Pagano, L [1 ]
机构：
[1] Univ Cattolica Sacro Cuore, Ist Ematol, Dept Hematol, I-00168 Rome, Italy
来源：
HAEMATOLOGICA | 2003年 / 88卷 / 02期
关键词：
lymphoproliferative disorders; rituximab; autaimmune hemolytic anemia;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
We administered rituximab monoclonal antibody to five patients suffering from a lymphoproliferative CD20-positive disease associated, at diagnosis or after starting treatment, with autoimmune hemolytic anemia (AIHA). After treatment with rituximab we observed an improvement of AIHA in all cases, and, in one case, improvement of the autoimmune thrombocytopenia associated with the AIHA. There were no relevant side effects.
引用
收藏
页码：223 / 225
页数：3
相关论文
共 50 条
  • [41] Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance
    Mitchell R Smith
    Oncogene, 2003, 22 : 7359 - 7368
  • [42] The use of rituximab, anti-CD20 monoclonal antibody, in pediatric transplantation
    Pescovitz, MD
    PEDIATRIC TRANSPLANTATION, 2004, 8 (01) : 9 - 21
  • [43] The anti-CD20 monoclonal antibody rituximab to treat acquired haemophilia A
    D'Arena, Giovanni
    Grandone, Elvira
    Di Minno, Matteo N. D.
    Musto, Pellegrino
    Di Minno, Giovanni
    BLOOD TRANSFUSION, 2016, 14 (03) : 255 - 261
  • [44] Rituximab, an anti-CD20 monoclonal antibody: History and mechanism of action
    Pescovitz, MD
    AMERICAN JOURNAL OF TRANSPLANTATION, 2006, 6 (05) : 859 - 866
  • [45] Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance
    Smith, MR
    ONCOGENE, 2003, 22 (47) : 7359 - 7368
  • [46] Current clinical trials of the anti-CD20 monoclonal antibody rituximab
    不详
    ONCOLOGY-NEW YORK, 2000, 14 (10): : 1437 - +
  • [47] Single dose of Anti-CD20 monoclonal antibody (rituximab) treatment in adults with refractory immune thrombocytopenic purpura (ITP).
    Tanaka, Eri
    Hayashi, Shuji
    Fujimaki, Katsumichi
    Fujita, Hiroyuki
    BLOOD, 2006, 108 (11) : 321A - 321A
  • [48] Treatment of mantle-cell lymphoma with Rituximab (chimeric monoclonal anti-CD20 antibody): Analysis of factors associated with response
    Foran, JM
    Cunningham, D
    Coiffier, B
    Solal-Celigny, P
    Reyes, F
    Ghielmini, M
    Johnson, PWM
    Gisselbrecht, C
    Bradburn, M
    Matthews, J
    Lister, TA
    ANNALS OF ONCOLOGY, 2000, 11 : 117 - 121
  • [49] Anti-CD20 chimeric monoclonal antibody (rituximab) treatment of immune-mediated thrombocytopenia associated with Crohn's disease
    Papadakis, KA
    Rosenbloom, B
    Targan, SR
    GASTROENTEROLOGY, 2003, 124 (02) : 583 - 583
  • [50] Anti-CD20 monoclonal antibody (rituximab) therapy in a child with refractory chronic autoimmune haemolytic anaemia
    Kerridge, I
    Hann, I
    Ethel, M
    Potter, M
    Prentice, HG
    INTERNAL MEDICINE JOURNAL, 2003, 33 (11) : 544 - U3
12345